We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Detection Method Diagnoses Ovarian Cancer from Blood, Urine and Saliva Samples

By LabMedica International staff writers
Posted on 10 Jul 2023
Print article
Image: Previously unidentified proteins suggest new way to diagnose ovarian cancer (Photo courtesy of Nagoya University)
Image: Previously unidentified proteins suggest new way to diagnose ovarian cancer (Photo courtesy of Nagoya University)

Detecting ovarian cancer in its preliminary stages, when it's most effectively treatable, poses a significant challenge. One potential method for identifying this cancer is through the analysis of extracellular vesicles (EVs), with a specific focus on small proteins known as exosomes that are discharged from the tumor. These proteins, being extracellular, can be gathered from body fluids such as blood, urine, and saliva. However, the practical application of these biomarkers has been hampered by a scarcity of reliable markers for ovarian cancer detection. Now, researchers have uncovered three previously undiscovered membrane proteins associated with ovarian cancer. Utilizing a novel technology of polyketone-coated nanowires, the research team successfully isolated these proteins, leading to a new detection approach for ovarian cancer detection.

The research, conducted at Nagoya University (Nagoya, Japan) involved extracting both small and medium/large EVs from high-grade serous carcinoma (HGSC), the most prevalent form of ovarian cancer. The researchers then analyzed them using liquid chromatography-mass spectrometry. Although the initial phase of the research was demanding and the validation of the identified proteins was particularly challenging, the researchers' persistent efforts paid off. After examining various antibodies, they finally identified suitable targets. The findings showed that small and medium/large EVs carry distinctly different molecules, and further study found that the small EVs make better biomarkers than their larger counterparts. The researchers identified FRα, Claudin-3, and TACSTD2 as the membrane proteins present in the small EVs connected to HGSC.

Following the successful identification of these proteins, the research team turned their attention to capturing EVs in a manner that would enable cancer detection. To achieve this, they developed polyketone chain-coated nanowires (pNWs), a technology particularly effective for extracting exosomes from blood samples. However, crafting the pNWs was not a straightforward process. The team had to experiment with multiple coatings before settling on polyketones, a completely new material for this application. Eventually, their hard work paid off as the polyketones proved to be a perfect match.

“Our findings showed that each of the three identified proteins is useful as a biomarker for HGSCs,” said Akira Yokoi of the Nagoya University Graduate School of Medicine who led the research group. “The results of this research suggest that these diagnostic biomarkers can be used as predictive markers for specific therapies. Our results allow doctors to optimize their therapeutic strategy for ovarian cancer, therefore, they may be useful for realizing personalized medicine.”

Related Links:
Nagoya University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.